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Introduction
Cardiovascular diseases (CVDs) are the leading causes of death among non-communicable diseases, posing a significant health and economic burden worldwide (1; 2) . The American Heart Association reported that 17.7 million people (representing 31% of all global deaths) died from CVDs in 2015, and this number is projected to rise to 23.6 million deaths by 2030 (3) . Dyslipidemia has been identified as a major risk factor for CVDs (4; 5; 6) . Thus, regulating and maintaining an optimal lipid profile is critical for the prevention of CVDs. In this regard, statin therapy and diet modification are two of the most commonly prescribed approaches (7; 8) . However, statins, among other commonly used lipid lowering pharmacotherapies (9) , have been established to pose some serious adverse effects, such as myopathies and hepatotoxicity (10; 11) . Thus, there is a demand to identify viable, anti-lipid agents that are able to pose cardioprotective effects without inducing any side-effects.
L-arginine is a semi-essential amino acid which our body derives either from dietary sources or from endogenous metabolism (12; 13) . L-arginine is involved in several biochemical processes, including polyamine synthesis, ammonia detoxification, immune modulation, and secretion of hormones such as glucagon and growth hormone and insulin (14; 15; 16) . What is more, this amino acid produces nitric oxide (NO), a key molecule involved in the regulation of cell metabolism, insulin signaling and secretion, neurotransmission and immune system function (17; 18) . It is suggested that L-arginine can be useful in improving lipid profile, due to its' potential to increase NO production. Therefore, L-arginine has been investigated as a potentially cardio-protective compound, and seven meta-analyses concluded that it can be an effective tool in blood pressure management (19) . Several trials investigated the potential of L-arginine supplementation for the treatment of abnormal lipid profile, however, the results are inconsistent. For instance, some trials report that L-arginine supplementation induced a reduction in circulating concentrations of lipid parameters (20; 21; 22; 23) , while others report no significant effect (18; 24; 25; 26; 27; 28; 29; 30) . Discrepancies in the findings may conceivably be attributed to the differences in study designs, characteristics of study participants, duration and the supplementation dosage applied in the trials. Therefore, we conducted a meta-analysis of those randomized controlled trials (RCTs) to examine the efficacy of L-arginine supplementation as a lipid-lowering agent.
Methods
We conducted and reported the present systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Supplementary Table 1 ) (31) for identification, screening, eligibility, and inclusion of articles.
This study was not prospectively registered. Participants, interventions, comparisons, outcomes, and study design (PICOS) are shown in Table 1 .
Search strategy
To carry out this meta-analysis, two independent investigators (A.H. and E.Gh) performed a systematic search of all articles published until April 2019 in the following online databases:
PubMed, Scopus, Cochrane Library, ISI Web of Science, and Google Scholar. We used the following Medical Subject Headings (MeSH) and corresponding keywords: ("arginine" OR "L-arginine") AND ("lipid" OR "hyperlipidaemia" OR "dyslipidemia" OR "cholesterol" OR "CHOL" OR "hypercholesterolemia" OR "lipoprotein" OR "hyperlipoproteinemia" OR "high density lipoprotein" OR "HDL" OR "low density lipoprotein" OR "LDL" OR "triglyceride"
OR "TG") AND ("Intervention Studies" OR "intervention" OR "controlled trial" OR "randomized" OR "randomised" OR "random" OR "randomly" OR "placebo" OR "assignment"). The two reviewers also performed screening of the reference lists of relevant review articles and original papers that were selected for full-text review to identify potential eligible studies. Additionally, an email alert service was employed to avoid missing any relevant articles. The language of the retrieved papers was restricted to English, while there were no restrictions regarding the year of publication.
Study selection
All studies retrieved from the electronic databases and reference lists were entered into endnote software (EndNote X6, Thomson Corporation, Stamford, USA) and duplicate studies were removed. In the next step, the titles and abstracts of the papers were examined by two independent reviewers (A.A and E.Gh) to exclude irrelevant articles. Afterwards, the full texts of the remaining publications were read and assessed according to the following four items: study design, participants, interventions and outcome measures. Finally, the studies were retained if they met the following inclusion criteria: (1) a randomized controlled design; (2) reporting the effect of L-arginine on at least one of the lipid profile parameters including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c), and highdensity lipoprotein cholesterol (HDL-c); (3) intervention duration longer than 4 weeks. Studies were excluded if they: (1) involved L-arginine supplementation in combination with some drugs or other types of supplements (minerals, vitamins or herbal supplements, unless a separate arm controlled the effect of the mixed substance); (2) reported duplicate data (in this case, the data with complete follow-up and outcome measures was included), (3) included adolescents as the population; (4) were not peer-reviewed articles (protocol or conference proceeding). Any disagreements regarding the process of study selection were resolved in consultation with the principal investigator (A.H).
Data extraction
The major demographic and clinical data from each of the selected studies were screened and extracted independently by two investigators (A.H and E.Gh) using a pre-designed Excel sheet.
Any controversy was solved via discussion with a third, independent researcher to reach a consensus. The extracted information was as follows: the first author's last name, publication year, study design, country, sample size, participants mean age, gender, baseline body mass index (BMI), follow-up duration, intervention duration (in weeks), type of intervention, dose of L-arginine (g/day), type of control, health status of the participants, and main results.
Corresponding authors were contacted if there were any missing data.
Quality assessment
The Cochrane Collaboration tool (32) was used for quality assessment, and it includes seven items, namely: randomization sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessors, incomplete outcome data, selective reporting, and other biases. Each domain was classified into three categories: low risk of bias, high risk of bias and unclear risk of bias. Finally, the overall quality of the studies was categorized into weak, fair, or good, if ˂3, 3, or ≥4 domains were rated as low risk, respectively. Quality assessment was performed independently by two reviewers (A.A and E.Gh), while any disagreements were resolved by consulting the third reviewer (A.H).
Statistical analysis
For carrying out the meta-analysis, we employed the STATA software (version 11; StataCorp). If outcome measures were reported in mmol/l, they were converted to mg/dL. The reviewers then extracted the mean difference between the baseline and endpoint data and the corresponding standard deviations (SD) in both intervention and control groups. If such data were not available, the mean difference was obtained by subtracting the mean value of the baseline-point from that of the endpoint. If SD of the mean difference was not reported, it was calculated using the following formula: SD = square root [(SD pre-treatment) 2 + (SD post-treatment) 2 -(2 × R × SD pretreatment × SD post-treatment)]. To ensure the meta-analysis was not sensitive to the selected correlation coefficient (R = 0.5), all analyses were repeated using correlation coefficients of 0.2 and 0.8. Where a standard error (SE) was only reported, SD was estimated using the following formula: SD = SE × √n (n being the number of subjects in each group). Using random-effects model developed by DerSimonian and Laird (33) , the summary estimate was pooled as weighted mean difference (WMD) and 95% confidence interval (CI). The inconsistency index (I 2 ) was used to quantify statistical heterogeneity in the meta-analyses, and values greater than 50% were considered indicative of high heterogeneity.
To identify the source of heterogeneity, subgroup analysis was conducted focusing on: mean age, baseline BMI, dose of L-arginine supplementation, study duration, and participant's health status. Sensitivity analysis was also performed to explore the extent to which inferences might depend on a particular study using the leave-one-out method (i.e. deleting one trail at a time and re-calculating the effect size). To assess publication bias, Begg (34) and Egger's (35) regression tests were performed. In all statistical analyses, level of significance was set at P < 0.05.
Results

Flow of study selection
A total of 2216 publications were identified after the search of the electronic databases, out of which 755 were removed as being duplicate (Figure 1) . By reviewing the title and abstracts of the remaining articles, 1438 publications not meeting the inclusion criteria were excluded. Subsequently, 23 full-text articles were carefully reviewed and 11 clinical trials were excluded because of the following reasons: five studies had a duration of supplementation period less than 4 weeks, one study enrolled adolescents, two studies involved interventions that were a combination of other components together with L-arginine and the design did not enable evaluating L-arginine effect only, one study enrolled less than 10 participants, and two articles reported the results from a same population. Finally, 12 trials including 15 treatment arms were considered eligible for the systematic review. However, one of the included articles (28) did not report the data required for the meta-analysis. We contacted the corresponding author of the study twice, but did not receive any response, and therefore it was subsequently, excluded, leaving 11 studies for inclusion in the meta-analysis.
Study and participant characteristics
Characteristics of the included trials are outlined in Table 2 . In total, 631 participants were enrolled in the selected articles, out of which 359 individuals were allocated to L-arginine supplementation group and 272 subjects to the control group. These studies were published between 1996 and 2019 and were carried out in the Iran (20; 21; 22; 23; 29) , Italy (27) , Poland (18; 24; 26) , Israel (28) , United Kingdom (30) , and Germany (25) . All studies except two (28; 30) adopted a parallel study design. , obese individuals (18; 20; 24; 29) , subjects with hypertriglyceridemia (25) , individuals with metabolic syndrome (23) , healthy subjects (21) , and those with impaired glucose tolerance and metabolic syndrome (27) . No major adverse effects attributable to intervention or control were reported in RCTs.
In a study by Pourghassem Gargari et al.
, there were three intervention groups (arginine + hypocaloric diet enriched in legumes (HDEL), arginine + HDEL + selenium, HDEL + selenium) and one control group (HDEL). We considered the result of the arginine + HDEL, and HDEL groups as one arm and the result of the arginine + HDEL + selenium and HDEL+ selenium groups as another arm. Furthermore, Rahimi et al. (22) and Dashtabi et al. (20) , included 2 different arginine doses in their trials (3 or 6 g/day); therefore, we considered these imputations as 4 different arms.
Quality assessment
Among 12 studies included in the present review, nine trials (18; 20; 21; 23; 24; 25; 26; 27; 29) were categorized as good quality, and 3 trials (22; 28; 30) were fair quality. The details of the risk of bias in individual studies according to the domains used by the Cochrane Collaborations tool are provided in Table 3 .
Findings from the systematic review
The present systematic review revealed that 3 trials (20; 21; 22) reported that L-arginine supplementation managed to reduce TC levels, while 8 studies (18; 23; 25; 26; 27; 28; 29; 30) failed to find any significant effect on this parameter. In terms of changes in TG levels, 3 trials observed a significant reduction after L-arginine supplementation in (20; 21; 23) , while 8 studies . Finally, L-arginine may induce favorable changes in HDL-c levels as confirmed in 2 trials (20; 21) , however, the remaining studies (22; 23; 24; 25; 26; 27; 28; 29; 30) did not reach the same conclusion.
Findings from the meta-analysis
In total, we pooled the data from 13 arms corresponding to 10 studies showed that the effect is not statistically significant in none of the subgroups (Table 4) .
Furthermore, removing each individual study by sensitivity analysis did not change the pooled effect size.
Ten studies including 533 participants from 13 intervention arms measured changes in serum HDL-c concentrations following L-arginine supplementation. Pooled results from the random-effects model revealed that L-arginine supplementation had no significant effect on serum HDL-c levels (WMD: 0.57 mg/dl; 95% CI: -1.28 to 2.43, P=0.54) ( Figure 5 ).
There was a significant heterogeneity among the studies (P˂0. =0.0%) were significant contributors to the between-study heterogeneity.
Besides, the subgroup analysis showed that L-arginine supplementation increases HDL levels in trials with a follow-up duration ˂10 weeks (WMD: 2.04 mg/dl; 95% CI: 0.52 to 3.56, P=0.01) ( Table 4) . Findings from the sensitivity analysis revealed that the exclusion of any single study from the analysis did not alter the overall effect.
Publication bias
Although the visual inspection of funnel plots showed slight asymmetries, no significant 
Discussion
To the best of our knowledge, this study is the first systematic review and meta-analysis that measured the effect of L-arginine supplementation on lipid profile by summarizing the data from published RCTs. Our results indicate that L-arginine supplementation was not able to induce changes in TC, LDL-c, and HDL-c concentrations however it did induce a significant decrease in TG levels. Subgroup analyses further confirmed that L-arginine supplementation imposed a significant TG-lowering effect in studies that implemented long-term treatment (≥10 weeks), as well as in studies where participants had a baseline BMI≥30 kg/m 2 , mean age ≥50 years, supplementation dosage ˂6 g/day, and where participants were type 2 diabetes or metabolic syndrome patients. Although the pooled effect size of L-arginine supplementation on HDL-c levels was not significant, subgroup analysis revealed that this effect was significant only in studies that lasted longer than 10 weeks.
In this meta-analysis, we concluded that L-arginine was able to induce favorable changes only on TG levels, while this was not observed in the case of other lipid parameters. The possible explanation for the observed lack of significant effect for all parameters except TG might be the fact that the included population had only TG levels above the recommended upper value according to the definition of metabolic syndrome. Thus, this observation may imply that individuals with higher TG levels are better respondents to L-arginine therapy.
The biological plausibility of lipid-associated L-arginine implications comes from the existing relationship between this amino acid and glucose metabolism. Human clinical trials have concluded so far that L-arginine can be an effective tool in reducing blood glucose levels in diabetes type 2 patients (36) , in increasing insulin sensitivity (37) and in improving insulin resistance (38) . One of the proposed explanations for the observed results is that insulin resistance of the adipocytes can lead to an increased release of fatty acids into the circulation.
Increased free fatty acid flux reaches the liver where it stimulates the assembly and secretion of very-low-density lipoprotein, which results in hypertriglyceridemia (39; 40) . Another possible mechanism might be related to the lowering effect of L-arginine on blood glucose, the decrease in blood glucose levels leads to an increase in the concentration of cyclic adenosine monophosphate which in turn decreases TG levels (41; 42) . Therefore, given the beneficial role of L-arginine in the glucose homeostasis, it is proposed that supplementation with this amino acid can lower serum TG levels (42; 43) .
Other putative mechanisms may be related to the arginine nitric oxide synthase pathway. All nitric oxide synthase isoforms utilize L-arginine as a substrate, which undergoes a two-step metabolic conversion, yielding at the end L-citrulline and NO (44) . Elevated NO production, consequently increases lipoprotein lipase activity (45) and finally, by performing hydrolysis of
TGs it reduces its concentration in the plasma (25; 46) . Animal study data also confirm Larginine to be an effective lipid lowering agent by decreasing the white fat expansion, and improving serum TG levels in rats (50) . Madeira et al. reported that dietary L-arginine supplementation increase concentrations of total lipids, very low-density lipoproteins (VLDL) and TG (51) . However, Hu et al. (52) reported that L-arginine supplementation decrease TG, and cholesterol levels in the plasma. In addition, He et al. (53) showed that L-arginine supplementation reduces VLDL, lipids and TG concentrations in piglets. However, Some animal studies reported that L-arginine might reduce cholesterol or lipoprotein levels by these mechanisms: 1) decrease the expression of hepatic 3-hydroxyl-3-methylglutaryl-CoA reductase mRNA, which shows interaction of Larginine with cholesterol metabolism (54) 2) increased the lipolysis as well as the oxidation of fatty acids; 3) increase plasma adiponectin levels which improved FFAs β-oxidation. On the other hand, others reported that possible TC increasing effect of L-arginine could be due to increased fat accretion in the carcass (55) . L-arginine can also increase the level of HDL-c through its effect on inflammation (47; 56; 57) .
L-arginine has generally been well tolerated when administered in small doses (≤ 30 g/day) (58) . There were some reported benign side effects, however, which include: abdominal pain, bloating, nausea and vomiting, airway inflammation, diarrhea, hypotension, worsening of asthma, and allergic reactions (58; 59; 60) . Furthermore, given that a major part of L-arginine is metabolized to ornithine and urea (58; 61) , patients with gout or renal function impairment should pay special caution when consuming it. Finally, due to its vasodilating properties, L-arginine has also been shown to interfere with certain medications (including Viagra and blood pressure medications) thus imposing negative reactions. (58) .
This meta-analysis has certain limitations that should be noted. Firstly, the included studies involved individuals with different health status, resulting in a heterogeneous sample.
Secondly, the sample sizes of individual trials were small, thus our results might more easily suffer from sample imbalances and an influence of baseline confounding factors. Third, the influence of gender remains unknown, since there was just one article that involved men.
Women have different sex hormones compared with men that may affect lipid profile, thus implying that L-arginine may impose gender-dependent effects. Lastly, most RCTs were not primarily designed to assess the effects of L-arginine on lipid concentrations. In order to draw straightforward conclusions regarding recommending L-arginine supplementation as a lipid lowering agent, we need more RCTs designed to specifically address this issue in a target population of patients with abnormal lipid profile.
This study also has its strengths. It is only systematic review and meta-analysis to investigate the effect of arginine supplementation on lipid profile. Our systematic search makes it unlikely that large reports were missed, and error and bias were minimized by independent, duplicate decisions on whole process of review by adhering to the PRISMA guidelines. Also, subgroup analysis and assessment of mean age, baseline BMI, dose of L-arginine, study duration, and health status were done on the overall effect sizes.
Conclusion
The current systematic review and meta-analysis demonstrated that L-arginine supplementation leads to a significant reduction in TG levels. However, no significant effect was observed in the case of other lipid parameters including TC, LDL-c, and HDL-c. In order to confirm the results of our study, further clinical trials that exclusively examine the effects of L-arginine on participants with dyslipidemia are required.
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